SAN FRANCISCO, Aug. 3, 2026 /PRNewswire/ -- AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a near-commercial Biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other...
Hence then, the article about ausperbio announces first patient dosed in clinical study of investigational hbv candidate ahb 171 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171 )
Also on site :
- Creality bringt den SPARKX i8 auf Indiegogo für 289 US-Dollar auf den Markt und bietet damit den schnellsten Druck ohne Spülabfall
- Golden Globe-Nominated Actress Makes Hilarious Confession About Burt Reynolds: ‘Burt Was Absolutely Obsessed with Three Things’
- Una sonda en órbita lunar detecta un nuevo cráter en la Luna, un hallazgo que ocurre “una vez en la vida”